Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

873 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
Matsuo E, Miyazaki Y, Tsutsumi C, Inoue Y, Yamasaki R, Hata T, Fukushima T, Tsushima H, Imanishi D, Imaizumi Y, Iwanaga M, Sakai M, Ando K, Sawayama Y, Ogawa D, Kawaguchi Y, Nagai K, Tsukasaki K, Ikeda S, Moriuchi Y, Yoshida S, Honda M, Taguchi J, Onimaru Y, Tsuchiya T, Tawara M, Atogami S, Yamamura M, Soda H, Yoshida Y, Matsuo Y, Nonaka H, Joh T, Takasaki Y, Kawasaki C, Momita S, Jinnai I, Kuriyama K, Tomonaga M. Matsuo E, et al. Among authors: tomonaga m. Int J Hematol. 2007 Feb;85(2):132-9. doi: 10.1532/IJH97.06157. Int J Hematol. 2007. PMID: 17321991 Clinical Trial.
Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group.
Sakai M, Miyazaki Y, Matsuo E, Moriuchi Y, Hata T, Fukushima T, Imaizumi Y, Imanishi D, Taguchi J, Iwanaga M, Tsushima H, Inoue Y, Takasaki Y, Tsuchiya T, Komoda M, Ando K, Horio K, Moriwaki Y, Tominaga S, Itonaga H, Nagai K, Tsukasaki K, Tsutsumi C, Sawayama Y, Yamasaki R, Ogawa D, Kawaguchi Y, Ikeda S, Yoshida S, Onimaru Y, Tawara M, Atogami S, Koida S, Joh T, Yamamura M, Matsuo Y, Soda H, Nonaka H, Jinnai I, Kuriyama K, Tomonaga M. Sakai M, et al. Among authors: tomonaga m. Int J Hematol. 2009 Apr;89(3):319-325. doi: 10.1007/s12185-009-0263-z. Epub 2009 Mar 6. Int J Hematol. 2009. PMID: 19266256
Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.
Tominaga-Sato S, Tsushima H, Ando K, Itonaga H, Imaizumi Y, Imanishi D, Iwanaga M, Taguchi J, Fukushima T, Yoshida S, Hata T, Moriuchi Y, Kuriyama K, Mano H, Tomonaga M, Miyazaki Y. Tominaga-Sato S, et al. Among authors: tomonaga m. Int J Hematol. 2011 Jul;94(1):81-89. doi: 10.1007/s12185-011-0883-y. Epub 2011 Jun 16. Int J Hematol. 2011. PMID: 21674360
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Mori S, Kamihira S, Tomonaga M, Miyazaki Y. Itonaga H, et al. Among authors: tomonaga m. Int J Hematol. 2012 Feb;95(2):209-13. doi: 10.1007/s12185-012-1005-1. Epub 2012 Jan 20. Int J Hematol. 2012. PMID: 22262141 Free article.
Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
Itonaga H, Tsushima H, Imanishi D, Hata T, Doi Y, Mori S, Sasaki D, Hasegawa H, Matsuo E, Nakashima J, Kato T, Horai M, Taguchi M, Matsuo M, Taniguchi H, Makiyama J, Sato S, Horio K, Ando K, Moriwaki Y, Sawayama Y, Ogawa D, Yamasaki R, Takasaki Y, Imaizumi Y, Taguchi J, Kawaguchi Y, Yoshida S, Joh T, Moriuchi Y, Nonaka H, Soda H, Fukushima T, Nagai K, Kamihira S, Tomonaga M, Yanagihara K, Miyazaki Y. Itonaga H, et al. Among authors: tomonaga m. Leuk Res. 2014 Jan;38(1):76-83. doi: 10.1016/j.leukres.2013.10.022. Epub 2013 Nov 5. Leuk Res. 2014. PMID: 24262285 Free article.
Chemokine expression in human erythroid leukemia cell line AS-E2: macrophage inflammatory protein-3alpha/CCL20 is induced by inflammatory cytokines.
Inoue Y, Tsushima H, Ando K, Sawayama Y, Sakai M, Yamasaki R, Matsuo E, Tsutsumi C, Imaizumi Y, Iwanaga M, Imanishi D, Taguchi J, Miyazaki Y, Tomonaga M. Inoue Y, et al. Among authors: tomonaga m. Exp Hematol. 2006 Jan;34(1):19-26. doi: 10.1016/j.exphem.2005.09.012. Exp Hematol. 2006. PMID: 16413387 Free article.
873 results